(129) identified the CD155/TIGIT axis as a key driver of immune evasion in pancreatic cancer, and combination immunotherapy (TIGIT/PD-1 co-blockade plus CD40 agonism) can induce antitumor responses in preclinical models. The gene discussed is TIGIT; the disease is pancreatic neoplasm.